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Autoimmune progesterone dermatitis (AIPD) is a rare
presentation of progesterone hypersensitivity, charac-
terized by recurrent cyclical eruptions during the luteal
phase of the menstrual cycle with a variable clinical
presentation.
A 42-year-old woman was evaluated in 2001 with a
dermatosis that had begun during her pregnancy the
previous year, at 32 weeks of gestation. Lesions were
localized to the face, neckline area, trunk and limbs, and
consisted of multiple pruritic and erythematous papules
and plaques with crusted erosions (Fig. 1a). The derma-
titis appeared every month, 5–6 days before the onset of
menses and gradually resolved 7–10 days later. The
patient had given birth six times and her only medication
was oral contraceptive pills (desogestrel 0.15 mg and
ethinyl oestradiol 0.02 mg, Mercilon; Organon, Lisbon,
Portugal), which she had taken intermittently for
20 years.
Histopathological examination of a biopsy taken from
a lesion revealed epidermal hyperplasia and perivascu-
lar inflammatory infiltration with mononuclear cells.
Three months later, she was admitted to our depart-
ment because of widespread dermatitis, predominantly
on the limbs (also affecting the palms and soles) and
trunk, and consisting of multiple annular erythematous
papules and patches with central vesiculation. On the
labial mucosa there were scattered painful eroded
lesions (Fig. 1b).
Histological examination of a second biopsy showed a
total epidermal necrosis and perivascular superficial
mononuclear infiltrate compatible with erythema
multiforme diagnosis. Direct immunofluorescence was
negative.
The patient was treated with prednisolone (1 mg ⁄
kg ⁄ day) and antihistamines with no improvement.
Subsequently, she discontinued all medical care.
Between November 2002 and May 2005 she reported
complete clinical remission. In August 2005 she
returned to our clinic because the dermatosis had
reappeared and was much more severe. An intradermal
test with medroxyprogesterone 50 mg ⁄ mL, performed
on the seventh day of the menstrual cycle, was positive
30 min after injection and persisted for 24 h. An
intradermal test with oestradiol was negative.
The patient was given treament with an intra-
muscular gonadotrophin-releasing hormone (GnRH)
agonist (leuprorelin acetate) for 6 months, achieving
amenorrhea and complete cutaneous clearing from the
first month. For ethical reasons, no attempt was made to
induce a flare with an intramuscular hormonal chal-
lenge. Hysterectomy and bilateral oophorectomy was
performed in March 2006, followed by oestrogen
supplementation. Two years after surgery, the patient
remains free of symptoms.
Approximately 50 cases of AIPD have been published
in the literature. The onset during pregnancy, as in our
patient, is very rare and may be related to the increase
in serum progesterone. Less than five cases have
been reported with or without associated spontaneous
abortion.1,2
The clinical features of AIPD include urticaria, angio-
oedema, erythema multiforme, erythema annulare
centrifugum, fixed drug eruptions, stomatitis or follicu-
litis, and there are no specific histological features.3–5
AIPD needs to be distinguished from many other
chronic dermatoses that worsen premenstrually. The
diagnosis requires, in addition to recurrent cutaneous
eruptions, two of the four main criteria: (i) a positive
intradermal skin test with progesterone; (ii) prevention
of the premenstrual flare by inhibiting ovulation;
(iii) demonstration of circulating antibodies to proges-
terone; and (iv) reproduction of symptoms with an
intramuscular hormonal challenge.1,5
It has been reported that AIPD may clear during
times of amenorrhea, or evolve towards remission with
treatment. Nevertheless, it is still not clear to us why
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there was complete remission for 30 months without
any treatment. Such an extended remission period has
not been described in other AIPD cases.
The mainstay of treatment for AIPD is to inhibit
endogenous progesterone secretion by suppressing ovu-
lation. In our case, the GnRH analogue showed efficacy,
but because of the side-effects, the clinical severity of the
disease, and because the patient did not want any more
children, a bilateral oophorectomy was performed. This
treatment has been reported in < 15 cases.3,5,6 Patients
who have undergone this procedure have had complete
resolution of their outbreaks after a series of medical
options, such as oestrogens, tamoxifen, GnRH, lutein-
izing hormone-releasing hormone, azathioprine, pred-
nisolone, dapsone or thalidomide have been tried. Slater
et al.6 described one exception to this rule; in patient 2
of their study, anaphylactoid symptoms improved after
bilateral salpingoophorectomy, but the patient still
required antihistamines to control flushing and bloat-
ing. In our opinion, oophorectomy should be considered
a valuable option in severe cases of AIPD with difficult
management, such as ours.
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Figure 1 (a) Multiple papules and plaques with crusted erosions;
(b) exudative erythema multiforme-like eruption.
 2010 The Author(s)
Journal compilation  2010 British Association of Dermatologists • Clinical and Experimental Dermatology, 35, e12–e13 e13
A memorable patient
